Cipla Limited has issued newspaper publications dated 5th May, 2026, in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The advertisements were published on 6th May, 2026, in Business Standard (English) and Sakal (Marathi), covering two distinct regulatory notices. The publications have also been uploaded on the company's official website at www.cipla.com .

Special Window for Physical Share Transfer and Dematerialisation

Pursuant to SEBI Circular No. HO/38/13/11(2026)-MIRSD-POD/3750/2026 dated 30th January, 2026, Cipla has notified shareholders of the opening of a special window for the lodgement of transfer and dematerialisation (demat) of physical shares. This special window will remain open until 4th February, 2027.

The eligibility criteria for lodgement under this special window are as follows:

Cases Excluded from the Special Window

The following cases will not be considered under this special window:

• Cases involving disputes between transferor and transferee
• Shares which have been transferred to the Investor Education and Protection Fund (IEPF)

Lock-In and Submission Details

Shares lodged for transfer pursuant to the above circular will only be issued in demat form and will be subject to a lock-in period of one year from the date of registration of transfer. During this lock-in period, such shares will not be transferred, dematerialised, or pledged.

Eligible shareholders wishing to avail this opportunity are requested to submit the requisite documents to:

KFIN Technologies Limited Registrar and Share Transfer Agent, Unit: Cipla Limited Plot No. 1, Plot No. 1A, 3rd Floor, Ganapathy Kadan Marg, Ananagarikapuram, Serilingampally, Hyderabad, Telangana - 500032 Tel. No.: +91 22 6108 1111 Email: cs@cipla.com

For any queries, shareholders may raise a service request at sgmward.nse@niftech.com or cs@cipla.com .

Notice of Loss of Share Certificates

In addition to the special window notice, Cipla also published a notice regarding the loss of share certificates in Business Standard (English) on 6th May, 2026. This notice was issued in compliance with applicable regulatory requirements under the SEBI Listing Regulations.

Regulatory Compliance and Publication Details

The newspaper publications were made in accordance with Regulation 30 of the SEBI Listing Regulations and communicated to the relevant stock exchanges. The details of the publications are summarised below:

The communication was signed by Rajendra Chopra, Company Secretary of Cipla Limited, on 6th May, 2026, and addressed to the listing departments of the relevant stock exchanges. Shareholders are encouraged to take advantage of the special window introduced in their interest before the closing date of 4th February, 2027.

Citigroup has maintained its positive outlook on Cipla by issuing a Buy rating with a target price of ₹1,530, as the pharmaceutical company navigates an increasingly competitive landscape in the generic drug market.

Market Competition Intensifies

The brokerage firm has highlighted the growing competition in the generic Symbicort market, with major pharmaceutical players Teva and Viatris emerging as significant competitors. This competitive pressure is reshaping the market dynamics and creating new challenges for existing players in the respiratory medication segment.

Regulatory Approval Critical for Growth

Citigroup emphasizes that timely US FDA approval has become increasingly urgent for Cipla's market positioning. The brokerage notes that securing regulatory clearance will be essential for the company to effectively compete against established players and capture meaningful market share in the generic Symbicort segment.

Strategic Market Positioning

The analysis suggests that Cipla's ability to sustain growth will largely depend on its success in obtaining regulatory approvals and establishing a strong foothold in the competitive generic pharmaceutical market. The company's strategic response to the competitive challenges posed by Teva and Viatris will be crucial for maintaining its market position.

The brokerage's positive rating reflects confidence in Cipla's potential to navigate these market challenges effectively, provided the company can secure the necessary regulatory approvals in a timely manner.